Senti Biosciences, Inc.

Contributing Author

Recent Articles by Senti Biosciences, Inc.

Sep-02	Senti Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference SNTI GlobeNewswire
Aug-14	Senti Biosciences to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech SNTI GlobeNewswire
Aug-12	Senti Bio Participates in Virtual Investor "What This Means" Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia SNTI GlobeNewswire
Aug-07	Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 SNTI GlobeNewswire
Aug-05	Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia SNTI GlobeNewswire
Jul-22	Senti Biosciences Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference SNTI GlobeNewswire
Jul-21	Senti Bio's Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum SNTI GlobeNewswire
Jul-18	Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors SNTI GlobeNewswire
Jun-30	Senti Bio Participates in Nasdaq Amplify Spotlight Series SNTI GlobeNewswire
Jun-24	Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference SNTI GlobeNewswire
Jun-18	Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia SNTI GlobeNewswire
Jun-09	Senti Biosciences Announces New Employment Inducement Grants SNTI GlobeNewswire
Jun-06	Senti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLC SNTI GlobeNewswire
May-22	Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar SNTI GlobeNewswire
May-22	Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202 SNTI GlobeNewswire
May-08	Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 SNTI GlobeNewswire
May-06	Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development SNTI GlobeNewswire
May-01	Senti Bio Releases Virtual Investor "What This Means" Segment SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire
Apr-30	Senti Bio to Present at the Citizens JMP Life Sciences Conference SNTI GlobeNewswire

Senti Biosciences, Inc.

Recent Articles by Senti Biosciences, Inc.

Upgrade your FINVIZ experience